今起北京执行新版医保商保药品“双目录”

Core Viewpoint - The implementation of the new national basic medical insurance drug list and the first commercial health insurance innovative drug list in Beijing on January 1, 2026, introduces 114 new drugs into the basic insurance reimbursement scope and 19 innovative drugs into the commercial insurance list, significantly benefiting patients [1][2]. Group 1: New Drug Inclusion - The new national medical insurance directory includes a total of 3,253 drugs, with 114 new drugs added, covering critical treatment areas such as cancer, chronic diseases, and rare diseases [1]. - Notable new drugs include the anti-cancer drug Lurbinectedin for triple-negative breast cancer, the diabetes medication Tirzepatide, and treatments for rare diseases like Langerhans cell histiocytosis [1]. Group 2: Commercial Insurance Drug List - The commercial insurance list includes 19 innovative drugs, focusing on high innovation, significant clinical value, and substantial patient benefits beyond the basic insurance coverage [1]. - Included innovative treatments are CAR-T cell immunotherapy products, biological agents for Alzheimer's disease, and specific drugs for Gaucher disease and short bowel syndrome [1]. Group 3: Patient Impact - An 8-year-old boy with high-risk neuroblastoma became one of the first beneficiaries of the new policy, with his treatment costs significantly reduced from tens of thousands of yuan annually to being partially covered by commercial insurance [2]. - The inclusion of GD2 antibody therapy in the commercial insurance list allows families to shift from full out-of-pocket expenses to insurance reimbursement, alleviating financial burdens [2]. Group 4: Transition Period and Adjustments - A 6-month transition period is established for drugs removed from the old national medical insurance directory, allowing them to still be reimbursed until June 30, 2026 [3]. - The Beijing Medical Insurance Bureau has mandated timely adjustments in drug supply at medical institutions and updates to the insurance information system to ensure patient access to necessary medications [3].